1 Safety was a secondary end point.
2 Safety was also assessed.
3 Safety was analysed by intention-to-treat.
4 Efficacy was analysed in the intention-to-treat population;
safety was analysed in all patients who received at least one
5 Safety was analysed in all patients who received at least one
6 ses were done on the intention-to-treat population, whereas
safety was analysed in all patients who received at least one
7 Safety was analysed in all patients who received at least one
8 Safety was analysed in all patients who received at least one
9 Safety was analysed in all patients who received the surgical
10 Safety was analysed in patients who received at least one dos
11 Safety was assessed as a secondary outcome as percentage of p
12 Safety was assessed by 3 validated bleeding scales (Global Us
13 In the same population,
safety was assessed by adverse effect monitoring.
14 Safety was assessed by adverse event reporting.
15 Safety was assessed by means of serial cardiac and thoracic i
16 Safety was assessed in all participants.
17 Safety was assessed in all patients who had received study dr
18 s overall survival in the intention-to-treat population and
safety was assessed in all patients who received at least one
19 Safety was assessed in all patients who received at least one
20 Safety was assessed in all patients who received at least one
21 Safety was assessed in all patients who received at least one
22 Safety was assessed in all patients who received at least one
23 Safety was assessed in all patients who received at least one
24 Safety was assessed in all patients who received one or more
25 Safety was assessed in all patients who received the interven
26 Safety was assessed in all patients who were assigned a treat
27 Safety was assessed in participants who received at least one
28 Safety was assessed in patients who received at least one dos
29 Safety was assessed in patients who received at least one dos
30 Safety was assessed in patients who received one or more dose
31 Safety was assessed in the all-participants-as-treated popula
32 Safety was assessed in treated patients who discontinued beca
33 Safety was assessed on the basis of adverse events, which wer
34 Safety was assessed on the basis of the treatment received.
35 Safety was assessed per protocol in all patients who received
36 Safety was assessed throughout.
37 SaFETy was associated with firearm violence in the validation
38 At baseline, greater individual-level
safety was associated with more adiposity.
39 Safety was checked every 2 wk by laboratory tests, the prosta
40 cts received IV angiotensin II were selected whether or not
safety was discussed.
41 Safety was evaluated over 180 days; immunogenicity and RSV in
42 Safety was evaluated throughout the study.
43 Safety was evaluated using clinical outcomes and plasma conce
44 Safety was generally similar between patients receiving immed
45 Safety was maintained throughout week 52; adverse events occu
46 Safety was not explicitly addressed in any study, but there w
47 SaFETy was not externally validated.
48 Safety was quantified as sensitivity in the rule-out zone, ac
49 Safety was the primary end point.
50 Safety was verified by oral food challenge to assess toleranc